Invasive Candidiasis in the Elderly: Considerations for Drug Therapy

B G J Dekkers, A Veringa, D J E Marriott, J M Boonstra, K C M van der Elst, F F Doukas, A J McLachlan, Jan-Willem C Alffenaar

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)
275 Downloads (Pure)

Abstract

Candida infections in the elderly are an important and expanding clinical problem, with significantly higher mortality in this group than in younger patients. The increasing problem of invasive Candida infections may be related to higher prevalence of immunocompromised older people and the emergence of treatment resistance. Older people, especially the frail and critically ill, are at higher risk of medication-related harmful effects due to changes in pharmacokinetics and pharmacodynamics, which may be further complicated by organ dysfunction, diminished homeostatic control, co-morbidities and polypharmacy. Here, we review the available options for the treatment of Candida infections and provide insights into the challenges surrounding the optimal use of antifungal drugs in the elderly.

Original languageEnglish
Pages (from-to)781-789
Number of pages9
JournalDrugs & Aging
Volume35
Issue number9
Early online date26-Jul-2018
DOIs
Publication statusPublished - Sept-2018

Keywords

  • LIPOSOMAL AMPHOTERICIN-B
  • CRITICALLY-ILL PATIENTS
  • D-GLUCAN ASSAY
  • FUNGAL-INFECTIONS
  • OLDER-PEOPLE
  • SUSCEPTIBILITY PATTERNS
  • CLINICAL-PHARMACOLOGY
  • ANTIFUNGAL AGENTS
  • ADULT PATIENTS
  • LIPID COMPLEX

Cite this